

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/596,521	06/15/2006	Jean-Francois Bonfanti	TIP-0063USPCT 7548	
27777 7590 06/22/2007 PHILIP S. JOHNSON JOHNSON & JOHNSON			EXAMINER	
			STOCKTON, LAURA LYNNE	
	N & JOHNSON PLAZA WICK, NJ 08933-7003		ART UNIT	PAPER NUMBER
			1626	
			[	
			MAIL DATE	DELIVERY MODE
			06/22/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	A1!4! N -	Anniinantia)			
•	Application No.	Applicant(s)			
	10/596,521	BONFANTI ET AL.			
Office Action Summary	Examiner	Art Unit			
	Laura L. Stockton, Ph.D.	1626			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D/ - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  36(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from the application to become ABANDON	DN. timely filed m the mailing date of this communication. IED (35 U.S.C. § 133).			
Status		•			
1) Responsive to communication(s) filed on  2a) This action is <b>FINAL</b> . 2b) This  3) Since this application is in condition for alloware closed in accordance with the practice under E	s action is non-final.  nce except for formal matters, p				
Disposition of Claims					
4)  Claim(s) <u>1-39</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5)  Claim(s) is/are allowed. 6)  Claim(s) is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) <u>1-39</u> are subject to restriction and/or of	wn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) $\square$ objected to by the drawing(s) be held in abeyance. S tion is required if the drawing(s) is c	ee 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)					
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO/SB/08)         Paper No(s)/Mail Date     </li> </ol>	4) Interview Summa Paper No(s)/Mail 5) Notice of Informa 6) Other:				

## DETAILED ACTION

Claims 1-39 are pending in the application.

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Due to the numerous variables in the claims, e.g. Q, G,  $Ar^1$ ,  $Ar^2$ ,  $Ar^3$ ,  $R^1$ ,  $R^{2a}$ ,  $R^{2b}$ ,  $R^6$ ,  $R^{6a}$ , Het, etc., and their widely divergent meanings, a precise listing of inventive groups cannot be made. The following groups are exemplary:

**Group I.** Claims 1-3, 8, 12-18, 25-31 (in-part), drawn to products of the formula wherein  $\mathbf{Q}$  is  $\mathrm{Ar}^2$ ; and  $\mathbf{R}^1$  is  $\mathrm{Ar}^1$ .

Application/Control Number: 10/596,521

Art Unit: 1626

**Group II.** Claims 1-3, 8-11, 13-20, 25-31 (in-part), drawn to products of the formula wherein  $\mathbf{Q}$  is  $\mathbf{R}^{6a}$ ; and  $\mathbf{R}^{1}$  is a monocyclic heterocycle.

**Group III.** Claims 1-8, 12-18, 21-23, 25-31 (inpart), drawn to products of the formula wherein  $\mathbf{Q}$  is pyrrolidinyl substituted with  $\mathbf{R}^6$ ; and  $\mathbf{R}^1$  is  $\mathbf{Ar}^1$ .

**Group IV.** Claims 1-8, 12-18, 21-31 (in-part), drawn to products of the formula wherein  $\mathbf{Q}$  is piperidinyl substituted with  $\mathbf{R}^6$ ; and  $\mathbf{R}^1$  is  $\mathbf{Ar}^1$ .

**Group V.** Claims 1-3, 8-11, 13-18, 25-31 (in-part), drawn to products of the formula wherein  $\mathbf{Q}$  is  $\mathrm{Ar}^2$ ; and  $\mathbf{R}^1$  is a monocyclic heterocycle.

**Group VI.** Claim 32 (in-part), drawn to a method of using products of the formula wherein  $\mathbf{Q}$  is  $\mathrm{Ar}^2$ ; and  $\mathbf{R}^1$  is  $\mathrm{Ar}^1$ .

**Group VII.** Claim 32 (in-part), drawn to a method of using the products of the formula wherein  $\mathbf{Q}$  is piperidinyl substituted with  $\mathbf{R}^6$ ; and  $\mathbf{R}^1$  is  $\mathbf{Ar}^1$ .

Application/Control Number: 10/596,521

Art Unit: 1626

**Group VIII.** Claims 33 (in-part), drawn to a process of preparing products of the formula wherein  $\mathbf{Q}$  is  $Ar^2$ ; and  $\mathbf{R}^1$  is  $Ar^1$ .

**Group IX.** Claims 33 (in-part), drawn to a process of preparing products of the formula wherein  $\mathbf{Q}$  is  $\mathbf{R}^{6a}$ ; and  $\mathbf{R}^1$  is a monocyclic heterocycle.

**Group X.** Claims 34-39 (in-part), drawn to products of the formula (VII-a) wherein  $\mathbf{Q}$  is pyrrolidinyl substituted with  $\mathbf{R}^6$ ; and  $\mathbf{R}^1$  is  $\mathbf{Ar}^1$ .

**Group XI.** Claims 34-39 (in-part), drawn to products of the formula (IX-a) wherein  $\mathbf{Q}$  is piperidinyl substituted with  $\mathbf{R}^6$ ; and  $\mathbf{R}^1$  is  $\mathbf{Ar}^1$ .

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Again, this list is not exhausted as it would be impossible under the time constraints due to the sheer

volume of subject matter instantly claimed. Therefore, applicant may choose to elect a single invention by identifying another specific embodiment not listed in the exemplary groups of the invention and the examiner will endeavor to group the same.

The claims herein lack unity of invention under PCT Rule 13.1 and 13.2 since the compounds defined in the claims lack a significant structural element qualifying as the special technical feature that defines a contribution over the prior art. The compounds claimed contain a 2-amino-benzimidazole ring, which does not define a contribution over the prior art. See, for example, CA Registry No. 934-32-7 in CA 29:16897 (1935). The substituents on the 2-amino-benzimidazole ring structure vary extensively and when taken as a whole result in vastly different compounds.

Accordingly, unity of invention is considered to be

lacking and restriction of the invention in accordance with the rules of unity of invention is considered to be proper.

Additionally, the vastness of the claimed subject matter and the complications in understanding the claimed subject matter imposes a burden on any examination of the claimed subject matter.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in

the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura L. Stockton whose telephone number is (571) 272-0710. The examiner can normally be reached on Monday-Friday from 6:15 am to 2:45 pm. If the examiner is out of the Office, the examiner's supervisor, Joseph McKane, can be reached on (571) 272-0699.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/596,521 Page 8

Art Unit: 1626

The Official fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Laura L. Stockton, Ph.D

Patent Examiner

Art Unit 1626, Group 1620 Technology Center 1600

June 19, 2007